1. Introduction {#sec1}
===============

TPO is a membrane-bound glycoprotein (102 kDa), found as a dimer \[[@B1]\]. Each monomer consists of 933 amino acid residues and contains a peroxidase domain, three additional extracellular domains, a transmembrane helix, and a short C-terminal intracellular tail \[[@B2]\]. The human*TPO* gene is located on chromosome 2p25 and spans approximately 150 Kb, containing 17 exons \[[@B3]\]. Mutations in*TPO* gene (particularly nonsynonymous cSNPs) can lead to severe defects in thyroid hormone production, due to total iodide organification defects (TIOD) or partial iodide organification defects (PIOD).*TPO* mutations are inherited as autosomal recessive traits \[[@B4]\]. Iodination of salt is the most effective and sustainable long-term public health measure for the prevention and control of iodide organification defects (IDD). But the iodination programme will not be effective if the gene mutations are the cause of dyshormonogenesis. Therefore, it is important to screen the percentage of people having gene mutations and iodine deficiency among the clinically identified thyroid patients.

Screening and identification of mutations in the*TPO* gene of patients with evidence of TIOD and PIOD have been done by several groups in different countries of the world like Argentina \[[@B4]\], Netherlands \[[@B5]\], Japan \[[@B6]\], Portugal \[[@B7]\], and China \[[@B8]\]. The present investigation is aimed at screening the mutations/polymorphisms in*TPO* gene and their effects on the function of*TPO* gene leading to hypothyroidism in the population of West Bengal to establish the genetic etiology of the disease.

2. Materials and Methods {#sec2}
========================

200 hypothyroid patients (case) and their corresponding sex and age matched 200 normal individuals (control) were screened depending on their clinical manifestations and detailed familial history from the Institute of Post Graduate Medical Education & Research (IPGME & R), Kolkata. Peripheral blood samples were collected on the basis of prior consent given by patients/normal individuals, families, and parents on behalf of minor children. To the extent possible, complete pedigree samples were obtained which included the proband, siblings, parents, and other blood relatives. Age and sex matched subjects with no goitre, no clinical evidence of hypothyroidism, and normal levels of serum T~3~, free T~4~ (FT~4~), TSH, and anti-TPO antibody were enrolled as normal (control). The experimental protocol was approved by the institutional ethics committee of IPGME & R, Kolkata. Clinical information includes complains like lethargy, cold intolerance, loss of memory, constipation, and weight gain. Personal history includes menarche, last child birth, abortion, cycle duration, and periodicity. Delayed milestones for children like sitting without support, speech, and walking were also documented.

Quantitative sandwich immunoassay kit (Siemens, India) was used to assay serum TSH level. Serum T~3~ or FT~4~ concentrations were determined by radioimmunoassay (RIA). Quantitative measurement of serum TPO antibody was performed using ELISA method. TPO antibody value \>60 IU/mL was considered as positive \[[@B9]\]. Radiolabeled iodine was administered to patients and control. Emittance of radioactivity was measured over the thyroid. Potassium perchlorate (a competitive inhibitor of iodide transport into the thyroid) was administered. Emittance of radioactivity was measured over the thyroid and compared to initial result.

The iodine in the urine is measured by a modification of the traditional colorimetric method of Sandell and Kolthoff (1937) \[[@B10]\]. This was done using the ammonium persulfate method as described by Pino et al. (1996) \[[@B11]\]. Urine was digested with ammonium persulfate. The iodine in the urine samples catalyses the reduction of ceric ammonium sulphate (yellow colour) to the cerous form (colourless) in the presence of arsenious acid. The degree of reduction in colour intensity of the yellow ceric ammonium sulphate is proportional to the iodine content in the urine sample.

Peripheral blood samples were collected from the case and control individuals. Genomic DNA was isolated from the blood leucocytes by using QIAamp Blood Kit (QIAGEN, Hilden, Germany). The human*TPO* gene (Exon 7 to Exon 14) was amplified by PCR. PCR was performed in a thermocycler (Applied Biosystems, Model number 9902) using specific primers for each of the exons ([Table 1](#tab1){ref-type="table"}). The reaction mixture (25 *μ*L) contained 40--100 ng of genomic DNA, 1.5 mM MgCl~2~, 100 *μ*M of each dNTP, 0.4 *μ*M of each primer, and 0.5 unit of Taq DNA polymerase (Applied Biosystems). Denaturation at 95°C for 30 seconds, annealing at 55--60°C for 30 seconds, and extension at 72°C for 30 seconds × 44 cycles were performed. The PCR product was analyzed in 2% agarose gel electrophoresis for verifying the size of the PCR product. PCR fragments were purified from agarose gel using Gel Extraction kit (Genei Bangalore).

The PCR products were sequenced by using Big Dye Terminator kit v3.1 (Applied Biosystems) in ABI Prism 377 DNA Sequencer (PE Applied Biosystems). Purified amplicons were used for sequencing reaction and the reaction mixture (10 *μ*L) contained 150 ng DNA, 5 *μ*M primer (either forward or reverse), 0.5 *μ*L BD, and 1.9 *μ*L 5 × BD buffer. Denaturation at 96°C for 10 seconds, annealing at 50--55°C for 10 seconds, and extension at 60°C for 4 min × 25 cycles were performed. 10 *μ*L PCR mix was added with solution I (10 *μ*L mq H~2~O, 2 *μ*L 125 mM EDTA, and pH 8.0) and solution II (50 *μ*L ehanol, 2 *μ*L Na-acetate, and pH 4.6). The mixture was kept in dark for 25 min and centrifuged at room temperature (13000 rpm for 30 min) and sample was dried in speed vac. Then, 12 *μ*L Hi-Di (formamide) was added in sample and stored at dark for 15 min and incubated at 96°C dry bath and we allowed the sample for snap chill in ice. Then, the sample was loaded in DNA Sequencer.

Sequences alignment between sequences of case and control individuals was performed to find the best matching piecewise (local) or global alignments of two query sequences using clustalW programme.

Polymorphism in the*TPO* gene, identified in this study, including nonsynonymous SNPs in the coding region, deletions, and insertions have been assayed*in vitro*. We used Invitrogen GeneArt Site-Directed Mutagenesis System for this purpose, for example, Glu 641 Lys, Asp 668 Asn, Thr 725 Pro, Asp 620 Asn, Ser 398 Thr, and Ala 373 Ser; these changes were incorporated into wild TPO cDNA through this method.

We used pcDNA3.1 (vector) for TPO cDNA cloning. Double restriction enzyme (EcoRI, KpnI) digestions were performed by incubating TPO cDNA and vector molecules with an appropriate amount of restriction enzyme, in its respective buffer as recommended by the supplier, and at the optimal temperature. The cut DNA fragment and vector are covalently joined together by DNA ligase.

Transformation is the method of introducing foreign DNA into bacterial cells. The recombinant plasmids (*TPO* cDNA + plasmid) were amplified in DH5 alpha competent cells. The uptake of recombinant plasmids by DH5 alpha cell was carried out in ice-cold CaCl~2~ (0--5°C) and subsequent heat shock (42°C for about 90 sec). Selection of DH5 alpha competent cells containing recombinant plasmids (TPO cDNA + plasmid) was done by ampicillin treatment. Plasmid was purified by use of the plasmid isolation kit (PureLink Quick Plasmid Miniprep Kit, Invitrogen). We used Invitrogen Lipofectamine Reagent for transfection. COS 7 cells were grown in 3.8 cm dishes in DMEM supplemented with 50 mL/L bovine calf serum and penicillin-streptomycin in 5% CO~2~ atmosphere at 37°C. When the cells reached \~90% confluence, they were transfected with 1 *μ*g of recombinant plasmid DNA (wild-type and mutant) per 3.8 cm dish with Lipofectamine. After incubation for 48 h, the cells were harvested for activity study. Cells were harvested with trypsin EDTA treatment and protein concentration was determined on a 100 *μ*L aliquot using the Bio-Rad protein assay (BioRad, Munchen, Germany). The cells were pelleted and subsequently suspended in 0.1% deoxycholate containing 1% aprotinin and incubated for 10 min at 4°C. The extract was microcentrifuged for 5 min, and the supernatant was removed to measure enzymatic activity using the guaiacol and I~3~ ^−^ assays. For the guaiacol assay, 50 *μ*L of the supernatant was assayed in a final volume of 750 *μ*L, containing 35 mM guaiacol and 0.5 mM H~2~O~2~ in 0.1 M Tris-HCl, pH 8.6. The absorbance at 470 nm was followed and activity was expressed as ΔA · min⁡^−1^ · mg  protein^−1^. For the I~3~ ^−^ assay, 25 *μ*L of the supernatant was used in a final volume of 750 *μ*L containing 0.1 M potassium phosphate, pH 7.5, 50 mM potassium iodide, and 0.25 mM H~2~O~2~. The absorbance at 353 nm was followed, and activity was expressed as ΔA · min⁡^−1^ · mg  protein^−1^. Spectrophotometric analysis was done on a Shimadzu UV-200.

Thirty micrograms of the deoxycholate extracted membrane protein fraction containing recombinant TPO and normal control TPO were electrophoresed on a 7.5% SDS-polyacrylamide gel. The gel was blotted onto nitrocellulose using a Bio-Rad Mini Protean 2 system (Bio-Rad Labs, Richmond, CA), followed by incubation with rabbit antihuman TPO antibody (abcam, EPR5379). TPO protein was visualized using ECL Western blotting detection reagent (abcam).

2.1. Statistical Methods {#sec2.1}
------------------------

*χ* ^2^ and Fisher exact tests were used to test the allelic and genotypic associations of each SNP. Student\'s*t*-test was used to calculate any statistically significant difference of continuous independent variables like age, TSH, and FT4 within the control and patient groups. All tests were done using GraphPad InStat software (GraphPad InStat software, San Diego, CA). Odds ratio and 95% confidential intervals were also calculated using the same software. A Bonferroni correction was applied for multiple testing.

3. Results {#sec3}
==========

The case and control groups were well balanced in terms of age and gender. There is no significant difference between two groups ([Table 2](#tab2){ref-type="table"}). Case individuals exhibited varied clinical manifestations. The associated clinical manifestations of hypothyroidism were goiter (65.5%), lethargy (61%), muscle cramp (55%), loss of memory (51%), hoarseness of voice (40.5%), weight loss (8% in male and 30% in female), constipation (55%), cold intolerance (60%), weight gain (45%) etc.,([Table 3](#tab3){ref-type="table"}).

The TSH level was significantly high and FT~4~ and T~3~ levels were significantly low in case population. In control population average serum TSH level was 2.51 ± 0.93 *μ*U/mL as compared to 35.14 ± 4.62 *μ*U/mL in case population. Similarly, serum FT~4~ level was 1.25 ± 0.10 ng/dL in control population as compared to 0.61 ± 0.27 ng/dL in case population. Serum T~3~ level was 1.64 ± 0.08 ng/dL in control population as compared to 0.65 ± 0.22 ng/dL in case population. 44 patients showed positive TPO antibody level ([Figure 1](#fig1){ref-type="fig"}).

The ^123^I uptake as shown by 83 patients at 3 hours was 48.1% ±7.90 and 75.3% ±5.90 of ^123^I was discharged at 60 min after the oral administration of KClO~4~ at a dose of 0.4 g in the perchlorate discharge test, confirming iodide organification defect in the thyroid gland. In our patient population, we found that 192 patients were within the level of 10--20 *μ*g/dL. In overall, 96% of the patients had UIE levels in the ranges of optimal iodine nutrition (10--20 *μ*g/dL) (WHO, UNICEF, and ICCIDD, 2001).

Mutation screening of*TPO* gene in both case and control groups, showed six nonsynonymous changes: c. 1117 G\>T: Ala 373 Ser, c. 1193G\>C: Ser 398 Thr, c. 1858 G\>A: Asp 620 Asn, c. 1921 G\>A: Glu 641 Lys, c. 2002G\>A: Asp668Asn, and c. 2173A\>C: Thr725Pro ([Figure 2](#fig2){ref-type="fig"}). After the Bonferroni correction for multiple comparisons a strong association was observed between the Asp 620 Asn, Glu 641 Lys, and Thr 725 Pro SNPs and hypothyroidism ([Table 4](#tab4){ref-type="table"}).

To measure wild-type and mutant enzyme activity, both the I^−^ and guaiacol assays were carried out. Wild-type recombinant TPO showed enzymatic activity in both assays. Mutant TPO showed relatively nonenzymatic reaction rate ([Table 5](#tab5){ref-type="table"}).

All mutants expressed reduced amount of TPO on the Western blot. In [Figure 3(a)](#fig3){ref-type="fig"}, Western blot showed expression of wild-type and mutated recombinant TPO. Lane 1 showed wild-type recombinant TPO. Lanes 2--4 showed recombinant TPO containing (2-Glu 641 Lys, 3-Asp 668 Asn, and 4-Thr 725 Pro) changes. In [Figure 3(b)](#fig3){ref-type="fig"}, Western blot showed expression of wild-type and mutated recombinant TPO. Lane 1 showed wild-type recombinant TPO. Lanes 2--4 showed recombinant TPO Containing (2-Asp 620 Asn, 3-Ser 398 Thr, and 4-Ala 373 Ser) changes.

4. Discussion {#sec4}
=============

The present study reveals clinical analysis of hypothyroidism in screened population. Hypothyroid patients exhibited significant increase in the level of serum TSH than control. As expected, patients showed lower level of T~3~ and FT~4~ as compared to control population. 83 patients showed positive result in the perchlorate discharge test confirming iodide organification defect in the thyroid gland. The urinary iodine excretion (UIE) of 96% patients was within the levels of 10--20 *μ*g/dL which were in the range of optimal iodine nutrition (10--20 *μ*g/dL) (WHO, UNICEF, and ICCIDD 2001). Therefore, UIE levels indicate that iodine deficiency is currently not a public health problem in our screened population.

Our study identified six different SNPs, among these three SNPs (Asp 620 Asn, Glu 641 Lys, and Thr 725 Pro) are significantly associated with hypothyroidism. We also try to find out the association between*TPO* gene polymorphisms and Anti-TPO level in our study subjects and we did not find any association (data not shown). However, several groups in different population like Tehranian population \[[@B12]\] and Iranian population \[[@B13]\] showed association between*TPO* gene polymorphisms and anti-TPO level. Our study needs much larger sample size which may help in better understanding of association between*TPO* gene polymorphisms and anti-TPO level.

Based on the literature, Exons 7--11 encode the catalytic center of the TPO protein (heme binding region) which is crucial for the enzymatic activity \[[@B14]\]. On the other hand, previous findings also indicate that Exons 7--14 harbor mutational hot spots \[[@B14]\]. Thus, mutations in these regions are expected to have major effects on TPO activity resulting in severe organification defect and severe hypothyroidism. In Glu 641 Lys, negative charged amino acid is replaced by positive charged amino acid. As we know, Threonine is the phosphorylation site of the protein which is important for the activation of the protein \[[@B15], [@B16]\]. Therefore, mutations in this amino acid may change the activity of TPO enzyme which may ultimately reduce the functional efficacy of the enzyme.

We established the effect of these polymorphisms through*in vitro* assay. Some polymorphisms (Glu 641 Lys, Thr 725 Pro, and Asp 620 Asn) were enzymatically inactive in both the guaiacol and iodide assays. They also showed reduced amount of TPO on the Western blot. This is a strong indication that the changes are present at crucial positions of the*TPO*gene, resulting in inactivated TPO.

5. Conclusions {#sec5}
==============

Thus, the above changes of amino acids may exert its effect on the structure and functional activity of TPO. Our study tried to detect the genetic etiology of this disease which may further help us to risk categorize for hypothyroidism. This study also helps to develop a genetic screening protocol for hypothyroidism, specifically for the Indian population.
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![T~3~ and FT~4~ level of patient and control (normal) populations. TSH and anti-TPO antibody level of patient and control (normal) populations.](IJE2014-390121.001){#fig1}

![Nucleotide polymorphism in*TPO* gene study population. (a) Nucleotide polymorphism in patient ID-147, Exon11, and ACT \> CCT (Thr \> Pro). (b) Nucleotide polymorphism in patient ID-6, Exon7, and AGC \> ACC (Ser \> Thr). (c) Nucleotide polymorphism in patient ID-183, Exon7, and GCG \> TCG (Ala \> Ser).](IJE2014-390121.002){#fig2}

![Western blot showing expression of wild-type and mutated recombinant TPO. (a) Lane 1, wild-type recombinant TPO. Lanes 2--4, recombinant TPO containing (2-Glu 641 Lys, 3-Asp 668 Asn, and 4-Thr 725 Pro) changes. In (b) Western blot showing expression of wild-type and mutated recombinant TPO. Lane 1, wild-type recombinant TPO. Lanes 2--4, recombinant TPO containing (2-Asp 620 Asn, 3-Ser 398 Thr, and 4-Ala 373 Ser) changes.](IJE2014-390121.003){#fig3}

###### 

Primer sequence used to screen the different exons of *TPO* gene.

  Exons     Primers                        Sequence                      Amplicon size (bp)
  --------- ------------------------------ ----------------------------- --------------------
  Exon 7    Forward                        5′-CTGGAGCTCTGTGAACAAGAA-3′   433
  Reverse   5′-CCCTGGGAATAGGACAAAGAAA-3′                                 
                                                                         
  Exon 8    Forward                        5′-CCCTACGTAACAAACCTGCAC-3′   474
  Reverse   5′-GGCTGTCAAGGAAGATGCTC-3′                                   
                                                                         
  Exon 9    Forward                        5′-CGTTGCTTAGAAGGCCTCAG-3′    444
  Reverse   5′-CTTGCAGTGAGCTGAGATCG-3′                                   
                                                                         
  Exon 10   Forward                        5′-ACAACCTGACCAGGCTTACG-3′    485
  Reverse   5′-CAGGACTCTGCCCTGCTG-3′                                     
                                                                         
  Exon 11   Forward                        5′-CTGCCCTGAGGGTGTAAGG-3′     446
  Reverse   5′-GAGAGGCTGGCAGCACACAG-3′                                   
                                                                         
  Exon 12   Forward                        5′-CTATCCCCAGATTGCTCCTG-3′    449
  Reverse   5′-GCTCAGTGAGTGACCACAGC-3′                                   
                                                                         
  Exon 13   Forward                        5′-GTGTGCTTCGAGGGTCTCTG-3′    485
  Reverse   5′-CCCTAGACCAGGTGGGATG-3′                                    
                                                                         
  Exon 14   Forward                        5′-CCATGTCCAGAGGAAAGGAG-3′    238
  Reverse   5′-CAGACTCAGGCAGGACAACC-3′                                   

###### 

Study population.

                    Case (*n* = 200)   Control (*n* = 200)   *P* value
  ----------------- ------------------ --------------------- -----------
  Sex                                                         
   Male             29 (14.5%)         32 (16%)              0.88
   Female           171 (85.5%)        168 (84%)             0.80
  Age (Mean ± SD)   29.85 ± 19.51      30.38 ± 12.90          

###### 

Clinical manifestations of case at initial presentation.

  Clinical manifestations   Case (*n* = 200)   \%     Control (*n* = 200)   \%    *P* value
  ------------------------- ------------------ ------ --------------------- ----- -----------
  \*Family history                                                                 
   Present                  93                 46.5   6                     3     \<0.0001
   Absent                   107                53.5   194                   97    
  \*Goiter                                                                         
   Present                  131                65.5   ---                   ---    
  \*Weight gain                                                                    
   Yes                      90                 45     67                    34    0.024
   No                       110                55     133                   66    
  Loss of memory                                                                   
   Yes                      102                51     90                    45    0.27
   No                       98                 49     110                   55    
  \*Lethargy                                                                       
   Yes                      122                61     91                    46    0.002
   No                       78                 39     109                   54    
  \*Muscle cramp                                                                   
   Yes                      110                55     88                    44    0.03
   No                       90                 45     112                   56    
  \*Cold intolerance                                                               
   Yes                      120                60     113                   57    0.54
   No                       80                 40     87                    43    
  \*Constipation                                                                   
   Yes                      109                55     80                    40    0.005
   No                       91                 45     120                   60    

\*at the time of diagnosis.

###### 

Allele and Genotype distribution of TPO gene polymorphisms in the study.

  SNP             Allele   Allele frequency   Odds ratio (95% CI)   *P* value           Genotype   Case (*n* = 200)   Control (*n* = 200)   Odds ratio (95% CI)   *P* value                              
  --------------- -------- ------------------ --------------------- ------------------- ---------- ------------------ --------------------- --------------------- -------------------------------------- -------
  c\. 1117 G\>T   G        0.54               0.59                  1.23 (0.93--1.62)   0.17       GG                 34%                   35%                   Reference                               
  Ala 373 Ser     T        0.46               0.41                                                 GT                 40%                   48.5%                 GG versus GT: 0.85 (0.54--1.33)        0.54
                                                                                                   TT                 26%                   16.5%                 GG versus TT: 1.62 (0.94--2.81)        0.11
                                                                                                                                                                  GG + GT versus TT: 1.78 (1.09--2.90)   0.028
                                                                                                                                                                                                         
  c\. 1193G\>C    C        0.73               0.68                  0.79 (0.58--1.07)   0.14       CC                 57.5%                 49%                   Reference                               
  Ser 398 Thr     G        0.27               0.32                                                 GC                 30.5%                 37.5%                 CC versus GC: 0.69 (0.45--1.07)        0.12
                                                                                                   GG                 12%                   13.5%                 CC versus GG: 0.76 (0.41--1.40)        0.46
                                                                                                                                                                                                         
  c.1858 G\>A     G        0.90               0.96                  2.67 (1.47--4.85)   0.001      GG                 85.0%                 93.0%                 Reference                               
  Asp 620 Asn     A        0.10               0.04                                                 GA                 10.5%                 6.50%                 GG versus GA: 1.77 (0.86--3.64)        0.11
                                                                                                   AA                 4.5%                  0.50%                 GG versus AA: 9.85 (1.23--78.54)       0.008
                                                                                                                                                                  GG versus GA + AA: 2.34 (1.20--4.57)   0.011
                                                                                                                                                                                                         
  c\. 1921 G\>A   G        0.87               0.94                  2.34 (1.41--3.88)   0.001      GG                 77.5%                 89%                   Reference                               
  Glu 641 Lys     A        0.13               0.06                                                 GA                 18.5%                 11%                   GG versus GA: 1.93 (1.09--3.41)        0.022
                                                                                                   AA                 4.0%                  0.0%                  GG versus GA + AA: 2.35 (1.35--4.09)   0.002
                                                                                                                                                                                                         
  c\. 2002 G\>A   G        0.93               0.94                  1.18 (0.67--2.07)   0.56       GG                 86.5%                 88.5%                 Reference                               
  Asp 668 Asn     A        0.07               0.06                                                 GA                 12.5%                 11.5%                 GG versus GA: 1.11 (0.61--2.03)        0.73
                                                                                                   AA                 1.0%                  0.0%                                                          
                                                                                                                                                                                                         
  c\. 2173 A\>C   A        0.54               0.63                  1.45 (1.09--1.92)   0.01       AA                 35%                   41.0%                 Reference                               
  Thr 725 Pro     C        0.46               0.37                                                 AC                 37.5%                 44.0%                 AA versus AC: 1.00 (0.64--1.56)        0.99
                                                                                                   CC                 27.5%                 15.0%                 AA versus CC: 2.15 (1.24--3.71)        0.006
                                                                                                                                                                  AA + AC versus CC: 2.15 (1.31--3.53)   0.002

Chi-square test was used to compare the genotype and allele frequencies between cases and controls.

*P* value \< 0.05 is considered to be statistically significant.

###### 

Guaiacol and iodide oxidation activity of expressed human TPO protein.

  Mutation      Guaiacol oxidation   Iodide oxidation
  ------------- -------------------- ------------------
  Wild type     0.76 ± 0.07          0.90 ± 0.05
  Glu 641 Lys   ND                   ∗
  Asp 668 Asn   0.63 ± 0.07          0.69 ± 0.27
  Thr 725 Pro   ND                   ∗
  Asp 620 Asn   ND                   ∗
  Ser 398 Thr   0.70 ± 0.27          0.82 ± 0.29
  Ala 373 Ser   0.62 ± 0.09          ∗

Enzyme activity was activity expressed as Δ*A*·min^−1^·mg protein^−1^.

\*Comparable with nonenzymatic reaction rate (0.51 ± 0.24). ND: no detectable activity (\<10% of wild-type expressed TPO) \[[@B17]\].

[^1]: Academic Editor: Małgorzata Kotula-Balak
